We are live on ! Find out more
FTRE icon

Fortrea Holdings

22.06 USD
+0.72
3.37%
At close Updated Oct 15, 11:04 AM EDT
1 day
3.37%
5 days
8.3%
1 month
11.81%
3 months
23.17%
6 months
119.5%
Year to date
31.23%
1 year
127.66%
5 years
-26.71%
10 years
-26.71%
 

About: Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

Employees: 14,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 50%
Neutral 50%
Negative 0%
Neutral
GlobeNewsWire
10 days ago
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
Neutral
GlobeNewsWire
1 month ago
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 month ago
Fortrea to Participate in September Investor Conferences
DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:
Fortrea to Participate in September Investor Conferences
Positive
Benzinga
1 month ago
Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion
Fortrea (NASDAQ:FTRE) signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million.
Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion
Neutral
GlobeNewsWire
1 month ago
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials
Neutral
Seeking Alpha
1 month ago
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue
Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue
Positive
Zacks Investment Research
2 months ago
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
Positive
Zacks Investment Research
2 months ago
FTRE vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
FTRE vs. ARGX: Which Stock Is the Better Value Option?
Positive
Zacks Investment Research
2 months ago
Best Momentum Stock to Buy for July 31st
FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.
Best Momentum Stock to Buy for July 31st
Positive
Zacks Investment Research
2 months ago
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum
Fortrea Holdings Inc. (FTRE) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum
Price charts implemented using Lightweight Charts™